Q4 Preliminary Figures and 2026 Guidance Make DexCom (DXCM) Look Attractive

DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment according to consensus. Out of 22 analysts who covered the stock, 18 assigned Buy ratings and 3 gave Hold calls. With just 1 Sell rating, the stock carries a median 1-year price target of $85.56, implying almost 17% upside for investors.

smart.art/Shutterstock.com

On January 12, Morgan Stanley reiterated its Overweight rating on DexCom Inc (NASDAQ:DXCM) with a price target of $75. The rating follows the company’s preliminary announcement of fourth-quarter results, reporting U.S. revenues of $892 million and international revenues of $368 million. This results in a year-over-year topline growth of 11% and 18%, respectively, beating consensus estimates by almost 2% points.

For FY 2025, management is expecting an adjusted gross margin of around 61% and an adjusted operating margin of roughly 20%-21%. For 2026, the business is expected to generate between $5.16 billion and $5.25 billion in revenue, with an adjusted gross margin of 63-64% and an adjusted operating margin in the range of 22%-23%.

DexCom Inc (NASDAQ:DXCM) is a medical device company that sells continuous glucose monitoring (CGM) systems. These systems efficiently manage diabetes and metabolic conditions by tracking glucose levels every few minutes. Some of its products include DexCom G6, DexCom G7, DexCom Share, DexCom Real-Time API, and DexCom ONE.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.